Posted by Michael Wonder on 20 Jan 2022
Jyseleca (filgotinib) licensed for the treatment of adult patients with moderately to severely active ulcerative colitis in Great Britain
18 January 2022 - Galapagos announced today that the Medicines and Healthcare products Regulatory Agency has granted a marketing authorization for Jyseleca (filgotinib 200mg tablets), as a new treatment for ulcerative colitis for Great Britain.
The MHRA has licensed an additional indication for Jyseleca, an oral once-daily, JAK1 preferential inhibitor, for use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
